Creating Next Generation ADCs with Industry-Leading DAR Precision, Plasma Stability & Tumor-Selective Linker Payload Activation

Time: 11:30 am
day: Day Two


  • Showcasing LCB’s novel next-generation site-specific ADC platform technology
  • Demonstrating proprietary cancer-selective linker providing significantly improved therapeutic index
  • Highlighting tumor-specific and ultra-potent DNA-damaging crosslinking payload with superior efficacy and reduced toxicity